Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases)

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 2, 2013, Pages 199-210

  Lynch, Joseph P ^a   Clark, Nina M ^b   Zhanel, George G ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antimicrobial resistance; Carbapenemases; Enterobacteriaceae; Extended spectrum lactamases; Multidrug resistance

Indexed keywords

AVIBACTAM; BETA LACTAMASE; CARBAPENEMASE; CEFTAROLINE; CEFTAZIDIME; CEPHALOSPORIN; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; COLISTIN; DORIPENEM; ERTAPENEM; FOSFOMYCIN; MEROPENEM; MINOCYCLINE; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TEMOCILLIN; TIGECYCLINE;

BACTERIAL MUTATION; CITROBACTER; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FOOD CONTAMINATION; GEOGRAPHIC DISTRIBUTION; HUMAN; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PLASMID; PROTEUS; REVIEW; SERRATIA MARCESCENS; TRANSPOSON; WATER CONTAMINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS;

EID: 84872745484     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.763030     Document Type: Review

References (136)

1. Canton R, Akova M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012;18:413-31
2. El Salabi A, Walsh TR, Chouchani C. Extended spectrum beta-lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria. Crit Rev Microbiol 2012; [Epub ahead of print]
3. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8
4. Woodford N, Turton JF, Livermore DM. Multiresistant gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011;35:736-55
5. Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases from gram-negative bacteria. Annu Rev Microbiol 2011;65:455-78
6. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64(Suppl 1):i29-36
7. Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum betalactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother 2011;66:689-92
8. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010;23:320-6
9. Azap OK, Arslan H, Serefhanoglu K, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010;16:147-51
10. Laurent C, Rodriguez-Villalobos H, Rost F, et al. Intensive care unit outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae controlled by cohorting patients and reinforcing infection control measures. Infect Control Hosp Epidemiol 2008;29:517-24
11. Piednoir E, Thibon P, Borderan GC, et al. Long-term clinical and economic benefits associated with the management of a nosocomial outbreak resulting from extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Crit Care Med 2011;39:2672-7
12. Kang CI, Song JH, Chung DR, et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase- producing Escherichia coli. Int J Antimicrob Agents 2010;36:284-7
13. Chong Y, Ito Y, Kamimura T. Genetic evolution and clinical impact in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Genet Evolut 2011;11:1499-504
14. Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents 2011;38:108-17
15. Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011;37:415-19
16. Peirano G, van der Bij AK, Gregson DB, Pitout JD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum beta-lactamase- producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol 2012;50:294-9
17. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008;13(47
18. Koksal F, Ak K, Kucukbasmaci O, Samasti M. Prevalence and antimicrobial resistance patterns of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an Istanbul University Hospital. Chemotherapy 2009;55:293-7
19. Tinelli M, Cataldo MA, Mantengoli E, et al. Epidemiology and genetic characteristics of extended-spectrum beta-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. J Antimicrob Chemother 2012;67(12):2982-7
20. Urban C, Bradford PA, Tuckman M, et al. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis 2008;46:e127-30
21. Lautenbach E, Han J, Santana E, et al. Colonization with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in long-term care facility residents. Infect Control Hosp Epidemiol 2012;33:302-4
22. Dhanji H, Doumith M, Rooney PJ, et al. Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum beta-lactamases in nursing homes in Belfast, UK. J Antimicrob Chemother 2011;66:297-303
23. Ben-Ami R, Rodriguez-Bano J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682-90
24. Pitout JD, Gregson DB, Church DL, et al. Community-wide outbreaks of clonally related CTX-M-14 betalactamase-producing Escherichia coli strains in the Calgary health region. J Clin Microbiol 2005;43:2844-9
25. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011;66:1-14
26. Peirano G, Richardson D, Nigrin J, et al. High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-betalactamase- producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother 2010;54:1327-30
27. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamaseproducing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006;50:498-504
28. Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-betalactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 2011;55:3485-90
29. Rossotti R, Orani A. Clinical management of ESBL-producing Enterobacteriaceae: the insidious role of fluoroquinolones. Eur J Clin Microbiol Infect Dis 2012;31:1517-22
30. Enoch DA, Brown F, Sismey AW, et al. Epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a UK district hospital; an observational study. J Hosp Infect 2012;81:270-7
31. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010;54:969-76
32. Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009;30:447-52
33. Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59:165-74
34. Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008;14:195-200
35. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents 2011;37:291-5
36. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum-beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. Antimicrob Agents Chemother 2008;52:2818-24
37. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006;58:205-10
38. Rossi F. The challenges of antimicrobial resistance in Brazil. Clin Infect Dis 2011;52:1138-43
39. Reinert RR, Low DE, Rossi F, et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007;60:1018-29
40. Jones CH, Tuckman M, Keeney D, et al. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob Agents Chemother 2009;53:465-75
41. Hirakata Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005;52:323-9
42. Chen YH, Hsueh PR, Badal RE, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect 2011;62:280-91
43. Prabaker K, Weinstein RA. Trends in antimicrobial resistance in intensive care units in the United States. Curr Opin Crit Care 2011;17:472-9
44. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85
45. Simner PJ, Zhanel GG, Pitout J, et al. Prevalence and characterization of extended-spectrum beta-lactamase-and AmpC beta-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. Diagnost Microbiol Infect Dis 2011;69:326-34
46. Peirano G, Sang JH, Pitondo-Silva A, et al. Molecular epidemiology of extended-spectrum-beta-lactamaseproducing Klebsiella pneumoniae over a 10 year period in Calgary, Canada. J Antimicrob Chemother 2012;67:1114-20
47. Ling TK, Xiong J, Yu Y, et al. Multicenter antimicrobial susceptibility survey of gram-negative bacteria isolated from patients with community-acquired infections in the People's Republic of China. Antimicrob Agents Chemother 2006;50:374-8
48. Lewis JS II, Herrera M, Wickes B, et al. First report of the emergence of CTX-M-type extended-spectrum betalactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007;51:4015-21
49. Doi Y, Adams J, O'Keefe A, et al. Community-acquired extended-spectrum beta-lactamase producers, United States. Emerg Infect Dis 2007;13:1121-3
50. Peirano G, Costello M, Pitout JD. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. Int J Antimicrob Agents 2010;36:19-23
51. Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010;51:286-94
52. Boyd DA, Tyler S, Christianson S, et al. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum betalactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob Agents Chemother 2004;48:3758-64
53. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004;48:15-22
54. Endimiani A, Paterson DL. Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum beta-lactamases. Semin Respir Crit Care Med 2007;28:646-55
55. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010;65:1119-25
56. Ito H, Arakawa Y, Ohsuka S, et al. Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens. Antimicrob Agents Chemother 1995;39:824-9
57. Levast M, Poirel L, Carrer A, et al. Transfer of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae from Turkey to France. J Antimicrob Chemother 2011;66:944-5
58. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009;53:5046-54
59. Aktas Z, Bal C, Midilli K, et al. First IMP-1-producing Klebsiella pneumoniae isolate in Turkey. Clin Microbiol Infect 2006;12:695-6
60. Pitout JD. The latest threat in the war on antimicrobial resistance. Lancet Infect Dis 2010;10:578-9
61. Potron A, Poirel L, Verdavaine D, Nordmann P. Importation of KPC-2-producing Escherichia coli from India. J Antimicrob Chemother 2012;67:242-3
62. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602
63. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45:1151-61
64. Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004;39:55-60
65. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009;53:3365-70
66. Navon-Venezia S, Leavitt A, Schwaber MJ, et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009;53:818-20
67. Leavitt A, Navon-Venezia S, Chmelnitsky I, et al. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51:3026-9
68. Wei ZQ, Du XX, Yu YS, et al. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother 2007;51:763-5
69. Pavez M, Mamizuka EM, Lincopan N. Early dissemination of KPC-2-producing Klebsiella pneumoniae strains in Brazil. Antimicrob Agents Chemother 2009;53:2702
70. Monteiro J, Santos AF, Asensi MD, et al. First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. Antimicrob Agents Chemother 2009;53:333-4
71. Giani T, D'Andrea MM, Pecile P, et al. Emergence in Italy of Klebsiella pneumoniae sequence type 258 producing KPC-3 Carbapenemase. J Clin Microbiol 2009;47:3793-4
72. Tsakris A, Kristo I, Poulou A, et al. First occurrence of KPC-2-possessing Klebsiella pneumoniae in a Greek hospital and recommendation for detection with boronic acid disc tests. J Antimicrob Chemother 2008;62:1257-60
73. Samuelsen O, Naseer U, Tofteland S, et al. Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. J Antimicrob Chemother 2009;63:654-8
74. Lauderdale TL, Shi ZY, Lin CF, et al. KPC-2-producing sequence type 11 Klebsiella pneumoniae detected in Taiwan. Antimicrob Agents Chemother 2012;56:2207-8
75. Rhee JY, Park YK, Shin JY, et al. KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. Antimicrob Agents Chemother 2010;54:2278-9
76. Venkatachalam I, Teo J, Balm MN, et al. Klebsiella pneumoniae Carbapenemase-producing Enterobacteria in Hospital, Singapore. Emerg Infect Dis 2012;18:1381-3
77. Brink AJ, Coetzee J, Clay CG, et al. Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa. J Clin Microbiol 2012;50:525-7
78. Carrer A, Poirel L, Yilmaz M, et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother 2010;54:1369-73
79. Giani T, Conte V, Di Pilato V, et al. Escherichia coli from Italy producing OXA-48 carbapenemase encoded by a novel Tn1999 transposon derivative. Antimicrob Agents Chemother 2012;56:2211-13
80. Moquet O, Bouchiat C, Kinana A, et al. Class D OXA-48 carbapenemase in multidrug-resistant enterobacteria, Senegal. Emerg Infect Dis 2011;17:143-4
81. Benouda A, Touzani O, Khairallah MT, et al. First detection of oxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from Morocco. Ann Trop Med Parasitol 2010;104:327-30
82. Poirel L, Ros A, Carrer A, et al. Cross-border transmission of OXA-48-producing Enterobacter cloacae from Morocco to France. J Antimicrob Chemother 2011;66:1181-2
83. Cuzon G, Naas T, Lesenne A, et al. Plasmid-mediated carbapenem- hydrolysing OXA-48 beta-lactamase in Klebsiella pneumoniae from Tunisia. Int J Antimicrob Agents 2010;36:91-3
84. Cuzon G, Ouanich J, Gondret R, et al. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother 2011;55:2420-3
85. Pirs M, Andlovic A, Cerar T, et al. A case of OXA-48 carbapenemaseproducing Klebsiella pneumoniae in a patient transferred to Slovenia from Libya, November 2011. Euro Surveill 2011;16:20042
86. Potron A, Kalpoe J, Poirel L, Nordmann P. European dissemination of a single OXA-48-producing Klebsiella pneumoniae clone. Clin Microbiol Infect 2011;17:E24-6
87. Decre D, Birgand G, Geneste D, et al. Possible importation and subsequent cross-transmission of OXA-48-producing Klebsiella pneumoniae, France, 2010. Euro Surveill 2010;15(46
88. Williamson DA, Heffernan H, Sidjabat H, et al. Intercontinental transfer of OXA-181-producing Klebsiella pneumoniae into New Zealand. J Antimicrob Chemother 2011;66:2888-90
89. Castanheira M, Deshpande LM, Mathai D, et al. Early dissemination of NDM-1-and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob Agents Chemother 2011;55:1274-8
90. Koh TH, Cao DY, Chan KS, et al. Bla (OXA-181)-positive Klebsiella pneumoniae, Singapore. Emerg Infect Dis 2012;18:1524-5
91. Davies TA, Marie Queenan A, Morrow BJ, et al. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrob Chemother 2011;66:2298-307
92. Landman D, Babu E, Shah N, et al. Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration. J Antimicrob Chemother 2012;67:1427-31
93. Mataseje LF, Bryce E, Roscoe D, et al. Carbapenem-resistant gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). J Antimicrob Chemother 2012;67:1359-67
94. Hammerum AM, Toleman MA, Hansen F, et al. Global spread of New Delhi metallo-beta-lactamase 1. Lancet Infect Dis 2010;10:829-30
95. Zarfel G, Hoenigl M, Leitner E, et al. Emergence of New Delhi metallo-betalactamase, Austria. Emerg Infect Dise 2011;17:129-30
96. Poirel L, Hombrouck-Alet C, Freneaux C, et al. Global spread of New Delhi metallo-beta-lactamase 1. Lancet Infect Dis 2010;10:832
97. Samuelsen O, Thilesen CM, Heggelund L, et al. Identification of NDM-1-producing Enterobacteriaceae in Norway. J Antimicrob Chemother 2011;66:670-2
98. Nordmann P, Couard JP, Sansot D, Poirel L. Emergence of an autochthonous and community-acquired NDM-1-producing Klebsiella pneumoniae in Europe. Clin Infect Dis 2012;54:150-1
99. Struelens MJ, Monnet DL, Magiorakos AP, et al. New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill 2010;15(46
100. Poirel L, Revathi G, Bernabeu S, Nordmann P. Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. Antimicrob Agents Chemother 2011;55:934-6
101. Poirel L, Benouda A, Hays C, Nordmann P. Emergence of NDM-1-producing Klebsiella pneumoniae in Morocco. J Antimicrob Chemother 2011;66:2781-3
102. Moellering RC Jr. NDM-1-a cause for worldwide concern. N Engl J Med 2010;363:2377-9
103. Stone NR, Woodford N, Livermore DM, et al. Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-beta-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. J Antimicrob Chemother 2011;66:2677-8
104. Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase- United States, 2010. MMWR Morb Mortal Wkly Rep 2010;59:750
105. Bonnin RA, Poirel L, Naas T, et al. Dissemination of New Delhi metallobeta-lactamase-1-producing Acinetobacter baumannii in Europe. Clin Microbiol Infect 2012;18:E362-5
106. Pfeifer Y, Wilharm G, Zander E, et al. Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007. J Antimicrob Chemother 2011;66:1998-2001
107. Karthikeyan K, Thirunarayan MA, Krishnan P. Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. J Antimicrob Chemother 2010;65:2253-4
108. Chen Y, Zhou Z, Jiang Y, Yu Y. Emergence of NDM-1-producing Acinetobacter baumannii in China. J Antimicrob Chemother 2011;66:1255-9
109. Kaase M, Nordmann P, Wichelhaus TA, et al. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J Antimicrob Chemother 2011;66:1260-2
110. Espinal P, Fugazza G, Lopez Y, et al. Dissemination of an NDM-2-producing Acinetobacter baumannii clone in an Israeli rehabilitation center. Antimicrob Agents Chemother 2011;55:5396-8
111. Ghazawi A, Sonnevend A, Bonnin RA, et al. NDM-2 carbapenemase-producing Acinetobacter baumannii in the United Arab Emirates. Clin Microbiol Infect 2012;18:E34-6
112. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31-7
113. Huang CC, Chen YS, Toh HS, et al. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010. Int J antimicrob Agents 2012;40(Suppl):S4-10
114. Peterson LR. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 2008;14(Suppl 1):181-4
115. Zimhony O, Chmelnitsky I, Bardenstein R, et al. Endocarditis caused by extended-spectrum-beta-lactamaseproducing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 2006;50:3179-82
116. Wienke M, Pfeifer Y, Weissgerber P, et al. In vitro activity of tigecycline and molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from a University Hospital in South-Western Germany. Chemotherapy 2012;58:241-8
117. Bennett JW, Mende K, Herrera ML, et al. Mechanisms of carbapenem resistance among a collection of Enterobacteriaceae clinical isolates in a Texas city. Diagn Microbiol Infect Dis 2010;66:445-8
118. Han JH, Kasahara K, Edelstein PH, et al. Risk factors for infection or colonization with CTX-M Extended-Spectrum beta-Lactamase (ESBL)-Positive Escherichia coli. Antimicrob Agents Chemother 2012;56:5575-80
119. Lowe CF, McGeer A, Muller MP, Katz K. Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada. Antimicrob Agents Chemother 2012;56:3977-80
120. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007;45:88-94
121. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 2005;49:1017-22
122. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31
123. Anthony KB, Fishman NO, Linkin DR, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70
124. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51
125. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601
126. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006;43(Suppl 2):S89-94
127. Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis 2012;74(3):213-23
128. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943-50
129. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012;56:2108-13
130. de Cueto M, Lopez L, Hernandez JR, et al. In vitro activity of fosfomycin against extended-spectrum-betalactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006;50:368-70
131. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50
132. Lee SY, Park YJ, Yu JK, et al. Prevalence of acquired fosfomycin resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother 2012;67(12):2843-7
133. Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, et al. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 2012;67:2777-9
134. Ehmann DE, Jahic H, Ross PL, et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci USA 2012;109:11663-8
135. Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-beta-lactam beta-lactamase inhibitors. Curr Opin Microbiol 2011;14:550-5
136. Zhanel GG, Lawson C, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin beta-lactamase inhibitor combination. Drugs 2013